We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

295 hedge funds and large institutions have $2.05B invested in Ultragenyx Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 125 increasing their positions, 83 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

51% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 83

29% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 48

4.16% more ownership

Funds ownership: 97.37% → 101.53% (+4.2%)

3% more funds holding

Funds holding: 287 → 295 (+8)

8% more call options, than puts

Call options by funds: $27.9M | Put options by funds: $25.8M

5% less capital invested

Capital invested by funds: $2.16B → $2.05B (-$108M)

Holders
295
Holders Change
+8
Holders Change %
+2.79%
% of All Funds
3.63%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
62
Increased
125
Reduced
83
Closed
48
Calls
$27.9M
Puts
$25.8M
Net Calls
+$2.02M
Net Calls Change
-$26.3M

Top Buyers

1
AQR Capital Management
AQR Capital Management
Connecticut
+$72.5M
2
SI
Sofinnova Investments
California
+$69M
3
BG
Bellevue Group
Switzerland
+$53.5M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$46.3M
5
Two Sigma Investments
Two Sigma Investments
New York
+$40.1M

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$84M
2
BBA
Baker Bros. Advisors
New York
-$63.8M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$53.6M
4
SCM
Suvretta Capital Management
New York
-$46.4M
5
BNP Paribas Asset Management
BNP Paribas Asset Management
France
-$33.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
A
326
AlphaQuest
New York
– -$135K -5,859 Closed
EI
327
EFG International
– -$19.5K -848 Closed
QCG
328
Quadrant Capital Group
Ohio
– -$9.2K -400 Closed
AF
329
Advisornet Financial
Minnesota
– -$7.34K -319 Closed
FHC
330
First Horizon Corporation
Tennessee
– -$3.89K -169 Closed
EWP
331
Elevation Wealth Partners
California
– -$3.75K -163 Closed
MMCM
332
Murphy & Mullick Capital Management
New York
– -$2.3K -100 Closed
CT
333
Clearstead Trust
Maine
– -$1.89K -82 Closed
JSAM
334
J. Safra Asset Management
New York
– -$1.56K -68 Closed
BFS
335
Bare Financial Services
Pennsylvania
– -$1.03K -45 Closed
TPCW
336
TD Private Client Wealth
New York
– -$690 -30 Closed
CA
337
Clearstead Advisors
Ohio
– -$506 -22 Closed
HI
338
Horizon Investments
North Carolina
– -$460 -20 Closed
BIA
339
Bell Investment Advisors
California
– -$391 -17 Closed
WWA
340
Wealth Watch Advisors
Colorado
– -$299 -13 Closed
TM
341
Torren Management
California
– -$161 -7 Closed
SC
342
SouthState Corp
Florida
– -$115 -5 Closed
TFM
343
TFC Financial Management
Massachusetts
– -$46 -2 Closed
10 11 12 13
14

RARE Hedge Fund Activity: Q1 2026 in Review

295 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2026, worth a combined $2.05B — down 5% from $2.16B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new RARE positions and 48 closed out — a net gain of 14 holders — while 125 added to existing stakes and 83 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $72.5M. The largest seller was JP Morgan Chase, cutting an estimated $84M.

  • 295 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2026, up from 287 in Q4 2025.
  • Funds reported $2.05B of Ultragenyx Pharmaceutical stock for Q1 2026, down 5% quarter-over-quarter.
  • 62 funds opened new Ultragenyx Pharmaceutical positions in Q1 2026 and 48 closed out, a net change of +14 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q1 2026 was AQR Capital Management, an estimated $72.5M added.
  • The largest Ultragenyx Pharmaceutical seller in Q1 2026 was JP Morgan Chase, an estimated $84M sold.

Based on aggregated 13F filings for Q1 2026.